ERBB2 and breast cancer: Positron emission tomography (PET) using HER2 antibodies labeled with radionuclides such as 111In, 64Cu, and 89Zr demonstrates sensitive and specific HER2 uptake in HER2-positive metastatic and primary breast cancer, and it can also identify unsuspected HER2-positive lesions (8–11).